TN2009000049A1 - A pyrrolopyrazin as syk-kinase inhibitor - Google Patents

A pyrrolopyrazin as syk-kinase inhibitor

Info

Publication number: TN2009000049A1
Authority: TN; Tunisia
Prior art keywords: pyrrolopyrazin; syk; kinase inhibitor; prodrugs; compound
Prior art date: 2006-09-11

Application number

TN2009000049A

Other languages

English (en)

Inventor

Elizabeth M Allen

Kin T Yu

Timothy A Gillespy

A Zilberstein

Paul Eynott

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-11

Filing date

2009-02-17

Publication date

2010-08-19

2009-02-17 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-08-19 Publication of TN2009000049A1 publication Critical patent/TN2009000049A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TN2009000049A 2006-09-11 2009-02-17 A pyrrolopyrazin as syk-kinase inhibitor TN2009000049A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82516806P	2006-09-11	2006-09-11
PCT/US2007/078103 WO2008033798A2 (fr)	2006-09-11	2007-09-11	Inhibiteur de kinases

Publications (1)

Publication Number	Publication Date
TN2009000049A1 true TN2009000049A1 (en)	2010-08-19

Family

ID=39032357

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TN2009000049A TN2009000049A1 (en)	2006-09-11	2009-02-17	A pyrrolopyrazin as syk-kinase inhibitor
TN2009000050A TN2009000050A1 (en)	2006-09-11	2009-02-17	Production method of methane gas from olive mill waste

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TN2009000050A TN2009000050A1 (en)	2006-09-11	2009-02-17	Production method of methane gas from olive mill waste

Country Status (32)

Country	Link
US (2)	US8658649B2 (fr)
EP (1)	EP2094708B1 (fr)
JP (1)	JP5161237B2 (fr)
KR (1)	KR101443056B1 (fr)
CN (2)	CN101511838A (fr)
AR (1)	AR062745A1 (fr)
AU (1)	AU2007296592B8 (fr)
BR (1)	BRPI0716781A2 (fr)
CA (1)	CA2663175C (fr)
CL (1)	CL2007002617A1 (fr)
CO (1)	CO6160236A2 (fr)
CR (1)	CR10636A (fr)
DK (1)	DK2094708T3 (fr)
ES (1)	ES2437318T3 (fr)
GT (1)	GT200900055A (fr)
HN (1)	HN2009000455A (fr)
IL (1)	IL197381A (fr)
MA (1)	MA30781B1 (fr)
MX (1)	MX2009002616A (fr)
MY (1)	MY148107A (fr)
NI (1)	NI200900021A (fr)
NO (1)	NO20091265L (fr)
NZ (1)	NZ575496A (fr)
PE (1)	PE20081372A1 (fr)
PT (1)	PT2094708E (fr)
RU (1)	RU2440352C2 (fr)
TN (2)	TN2009000049A1 (fr)
TW (1)	TWI399379B (fr)
UA (1)	UA94622C2 (fr)
UY (1)	UY30584A1 (fr)
WO (1)	WO2008033798A2 (fr)
ZA (1)	ZA200901073B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2250172T3 (da)	2008-02-25	2012-01-16	Hoffmann La Roche	Pyrrolopyrazinkinaseinhibitorer
JP5368485B2 (ja)	2008-02-25	2013-12-18	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼインヒビター
JP5284377B2 (ja)	2008-02-25	2013-09-11	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼ阻害剤
ATE517107T1 (de)	2008-02-25	2011-08-15	Hoffmann La Roche	Pyrrolopyrazinkinaseinhibitoren
CN101952295B (zh) *	2008-02-25	2013-11-20	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
AU2009223501A1 (en) *	2008-03-10	2009-09-17	Sanofi-Aventis	Treatment for ocular-related disorders
FR2929851B1 (fr) *	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
AR074437A1 (es)	2008-12-03	2011-01-19	Sanofi Aventis	Tratamiento para la glomerulonefritis
WO2010065690A1 (fr)	2008-12-04	2010-06-10	Sanofi-Aventis	Formes cristallines
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
JP5658274B2 (ja)	2009-12-23	2015-01-21	武田薬品工業株式会社	Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
RU2012152354A (ru)	2010-05-20	2014-06-27	Ф. Хоффманн-Ля Рош Аг	Производные пирролопиразина в качестве ингибиторов syk и jak
WO2011144585A1 (fr) *	2010-05-20	2011-11-24	F. Hoffmann-La Roche Ag	Dérivés de pyrrolo[2,3-b]pyrazine-7-carboxamide et leur utilisation comme inhibiteurs de jak et syk
EP2441755A1 (fr)	2010-09-30	2012-04-18	Almirall, S.A.	Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
US9056873B2 (en)	2011-06-22	2015-06-16	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
WO2014029732A1 (fr) *	2012-08-21	2014-02-27	F. Hoffmann-La Roche Ag	Pyrrolo[2,3-b]pyrazines comme inhibiteurs de syk
ES2656192T3 (es)	2013-07-31	2018-02-26	Gilead Sciences, Inc.	Inhibidores de SKY
MX2021009863A (es)	2019-03-21	2021-11-12	Onxeo	Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
WO2021089791A1 (fr)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
CN116969927B (zh) *	2023-06-07	2024-03-19	中南民族大学	一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1141949A (en)	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en)	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
US6075037A (en)	1994-06-09	2000-06-13	Smithkline Beecham Corporation	Endothelin receptor antagonists
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU734841B2 (en)	1996-11-19	2001-06-21	Amgen, Inc.	Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6312835B1 (en)	1997-02-13	2001-11-06	Queen's University At Kingston	Luminescent compounds and methods of making and using same
CN1134439C (zh)	1997-03-19	2004-01-14	艾博特股份有限两合公司	吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
WO1998047899A1 (fr)	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
CA2293621C (fr)	1997-08-05	2003-12-30	Robert Lee Dow	4-aminopyrrole(3,2-d)pyrimidines en tant qu'antagonistes du recepteur du neuropeptide y
ID27124A (id)	1997-10-20	2001-03-01	Hoffmann La Roche	Penghambat kinase bisiklik
WO1999045016A2 (fr)	1998-03-06	1999-09-10	Metabasis Therapeutics, Inc.	Nouveaux promedicaments pour composes contenant du phosphore
AU3210799A (en)	1998-04-02	1999-10-25	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
JP2002510685A (ja)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	性腺刺激ホルモン放出ホルモン拮抗薬
AU3851199A (en)	1998-05-26	1999-12-13	Chugai Seiyaku Kabushiki Kaisha	Heterocyclic indole derivatives and mono- or diazaindole derivatives
BR9913888A (pt)	1998-09-18	2002-01-08	Basf Ag	Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
DZ3377A1 (fr) *	1999-12-24	2001-07-05	Aventis Pharma Ltd	Azaindoles
US6770666B2 (en)	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de)	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
AU2001247589A1 (en)	2000-03-20	2001-10-03	Axys Pharmaceuticals, Inc.	Non-amidine containing protease inhibitors
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en)	2000-05-03	2004-01-06	Tularik Inc.	Pyrazole antimicrobial agents
JP2004503553A (ja)	2000-06-14	2004-02-05	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	６，５−縮合二環式複素環
CA2424222A1 (fr)	2000-10-02	2002-04-11	Merck & Co., Inc.	Inhibiteurs de la prenyl-proteine transferase
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (fr)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthese de composes heterocycliques faisant appel a une technologie micro-onde
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
IL161576A0 (en)	2001-10-26	2004-09-27	Aventis Pharma Inc	Benzimidazoles and analogues and their use as protein kinases inhibitors
US20040082365A1 (en) *	2002-07-18	2004-04-29	Celerica Ltd	Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (fr)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines utilisées comme inhibiteurs de kinases
WO2005014543A1 (fr)	2003-08-06	2005-02-17	Japan Tobacco Inc.	Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
AU2005269387A1 (en) *	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
WO2006052712A1 (fr)	2004-11-08	2006-05-18	Baxter International Inc.	Compositions nanoparticulaires d'inhibiteurs de la tubuline
WO2006058074A1 (fr) *	2004-11-22	2006-06-01	Vertex Pharmaceuticals Incorporated	Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
US20110112101A1 (en)	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders

2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 CA CA2663175A patent/CA2663175C/fr not_active Expired - Fee Related
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/fr active Search and Examination
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/fr active Active
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active Expired - Fee Related
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UA94622C2 (en)	2011-05-25
KR20090063214A (ko)	2009-06-17
JP5161237B2 (ja)	2013-03-13
CA2663175C (fr)	2012-03-13
CA2663175A1 (fr)	2008-03-20
US8658649B2 (en)	2014-02-25
AU2007296592A1 (en)	2008-03-20
PT2094708E (pt)	2014-01-07
RU2440352C2 (ru)	2012-01-20
TWI399379B (zh)	2013-06-21
KR101443056B1 (ko)	2014-09-22
PE20081372A1 (es)	2008-11-27
WO2008033798A3 (fr)	2008-05-15
MY148107A (en)	2013-02-28
DK2094708T3 (da)	2014-01-27
RU2009113615A (ru)	2010-10-20
IL197381A0 (en)	2009-12-24
IL197381A (en)	2013-11-28
US20140142110A1 (en)	2014-05-22
ZA200901073B (en)	2009-12-30
AU2007296592B2 (en)	2011-12-15
US20100035884A1 (en)	2010-02-11
WO2008033798A2 (fr)	2008-03-20
MX2009002616A (es)	2009-03-24
CN103804383A (zh)	2014-05-21
EP2094708A2 (fr)	2009-09-02
GT200900055A (es)	2010-07-28
BRPI0716781A2 (pt)	2014-11-18
CO6160236A2 (es)	2010-05-20
HN2009000455A (es)	2012-02-13
TW200829590A (en)	2008-07-16
ES2437318T3 (es)	2014-01-10
NI200900021A (es)	2010-01-29
NO20091265L (no)	2009-04-03
JP2010502767A (ja)	2010-01-28
CN101511838A (zh)	2009-08-19
EP2094708B1 (fr)	2013-10-23
NZ575496A (en)	2011-09-30
MA30781B1 (fr)	2009-10-01
CR10636A (es)	2009-03-20
UY30584A1 (es)	2008-05-02
TN2009000050A1 (en)	2010-08-19
AR062745A1 (es)	2008-12-03
AU2007296592B8 (en)	2012-01-12
CL2007002617A1 (es)	2008-05-16

Publication	Publication Date	Title
TN2009000049A1 (en)	2010-08-19	A pyrrolopyrazin as syk-kinase inhibitor
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1940839E (pt)	2013-10-10	Inibidores de piridopirimidinona pi3k alfa
WO2006123113A3 (fr)	2007-01-04	Composes chimiques
MX2009000884A (es)	2009-06-05	Derivados de piridizinona.
PH12012502057A1 (en)	2015-09-14	Compounds for inhibiting mitotic progression
MX2009003834A (es)	2009-04-22	Derivados de pirrolidina como inhibidores de iap.
SG179418A1 (en)	2012-04-27	Inhibitors of the hedgehog pathway
NZ585460A (en)	2013-02-22	Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009016460A8 (fr)	2009-10-15	Composés pyrazoles
MX2010004263A (es)	2010-05-03	Inhibidores de quinasa c-fms.
MY151003A (en)	2014-03-31	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2008022286A3 (fr)	2008-04-17	petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
MX2009011579A (es)	2009-11-11	Pirimidinonas como moduladores de caseina cinasa ii (ck2).
MX2009005691A (es)	2009-08-07	Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
TNSN08191A1 (en)	2009-10-30	Kinase inhibitors
TN2010000038A1 (en)	2011-09-26	Organic compounds
PH12013500695A1 (en)	2017-08-09	Pharmaceutical compositions containing a dgat1 inhibitor
TW200800951A (en)	2008-01-01	Substituted imidazole compounds as KSP inhibitors
UA97821C2 (en)	2012-03-26	Cyclized derivatives as eg-5 inhibitors
EA200900631A1 (ru)	2009-12-30	Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
TNSN08369A1 (en)	2009-12-29	Benzimidazole derivatives
UA96969C2 (en)	2011-12-26	Acylaminopyrazoles as fgfr inhibitors
TNSN08242A1 (en)	2009-10-30	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof